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Dyslipidemia is one of the most impor-
tant known and modifiable risk factors 
for the development of coronary heart dis-
ease (CHD) [1]. Of prognostic relevance 
are changes in blood lipid concentrations 
(dyslipidemia), in particular elevated con-
centrations of total cholesterol and of cho-
lesterol attached to low-density lipopro-
tein (LDL) as well as low concentrations 
of cholesterol attached to high-density li-
poprotein (HDL) [2].
Total and HDL cholesterol concen-
trations are frequently used to assess the 
prevalence of dyslipidemia in the popula-
tion [3]. However, responsiveness to ther-
apy and the benefit of lipid-lowering med-
ication for cardiovascular risk have un-
til now only been demonstrated for LDL 
cholesterol. Evidence-based treatment 
guidelines therefore refer primarily to this 
parameter [4, 5, 6, 7]. Compared to LDL 
cholesterol, total and HDL cholesterol 
concentrations are influenced to a far less-
er degree by the time at which food was 
last ingested [3, 8, 9]. In large epidemio-
logical studies it is frequently not feasible 
or feasible for part of the survey popula-
tion only to determine fasting blood lip-
id concentrations following a sufficiently 
long fasting period. Thus, in many coun-
tries it has become established practice to 
measure total cholesterol and HDL cho-
lesterol concentrations in order to assess 
dyslipidemia for health monitoring of the 
population [3, 10, 11]. The percentage of 
persons with dyslipidemia in the popula-
tion in which the person affected is aware 
of it (level of awareness) and the percent-
age of people being treated for diagnosed 
dyslipidemia (level of treatment) are addi-
tional indicators for the implementation 
of prevention programmes.
This report is intended to provide cur-
rent estimates of the distribution of to-
tal and HDL cholesterol concentrations 
among adults 18–79 years of age in Ger-
many. In addition, it provides analysis of 
the overall prevalence of dyslipidemia and 
the levels of awareness and treatment of 
dyslipidemia using measured total choles-
terol concentrations, using self-reports of 
participants as to whether they have ev-
er been diagnosed with dyslipidemia and 
using documented consumption of lipid-
lowering medication.
Methods
The German Health Interview and Ex-
amination Survey for Adults (“Studie zur 
Gesundheit Erwachsener in Deutsch-
land”, DEGS) is part of the health mon-
itoring system at the Robert Koch Insti-
tute (RKI). The concept and design of 
DEGS are described in detail elsewhere 
[12, 13, 14, 15, 16]. The first wave (DEGS1) 
was conducted from 2008–2011 and com-
prised interviews, examinations and tests 
[17, 18]. The target population compris-
es the resident population of Germany 
aged 18–79 years. DEGS1 has a mixed de-
sign, which permits both cross-sectional 
and longitudinal analyses. For this pur-
pose, a random sample from local popu-
lation registries was drawn in addition to 
persons who participated in the German 
National Health Interview and Examina-
tion Survey 1998 (GNHIES98) and also 
took part in DEGS1. A total of 8,152 per-
sons participated, including 4,193 first-
time participants (response rate 42%) 
and 3,959 persons who previously par-
ticipated in GNHIES98 (response rate 
62%). There were 7,238 persons who at-
tended one of the 180 examination cen-
tres, and 914 were interviewed only. 
Across the age range 18–79 years, the net 
sample (n=7,988, including 7,116 in study 
centres) permits representative cross-
sectional analyses as well as time trend 
analyses based on comparison with GN-
HIES98 [16]. The data of revisiting GN-
HIES98 participants can be used for lon-
gitudinal analyses. The cross-sectional 
and longitudinal analyses are conducted 
using a weighting factor, which corrects 
deviations in the sample from the popu-
lation structure (as of 31 Dec 2010) with 
respect to age, sex, region and nationali-
ty as well as type of municipality and ed-
ucation [16]. A separate weighting factor 
was generated for the examination part of 
the study. The calculation of the weight-
ing factor also considered the probability 
of repeat participation among GNHIES98 
participants, based on a logistic regres-
sion model. A non-response analysis and 
comparison of selected indicators using 
data from census statistics show that the 
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net sample is highly representative of the 
resident population aged 18–79 years in 
Germany [16].
Study population
The following analyses are based on data 
from men and women who participated in 
the examinations in DEGS1 and for whom 
measurements of serum total cholesterol 
concentration (n=7,038) and serum HDL 
cholesterol concentration (n=7,045) were 
available. Where additional variables are 
included, the overall number of observa-
tions is slightly lower due to missing da-
ta and the total number is shown accord-
ingly.
Data and definitions
Laboratory values were determined using 
serum samples obtained from blood taken 
in the study centres [18]. Serum concen-
trations of total cholesterol and HDL cho-
lesterol were determined within 6 weeks 
after blood collection using an enzymat-
ic procedure (Architect ci8200, Abbott, 
Germany) in serum samples that had 
been frozen (−40°C) over the intervening 
period and had not previously been un-
thawed. The processes of taking blood, 
obtaining samples and transporting sam-
ples as well as the analyses were carried 
out in accordance with standardised op-
erational procedures [15, 17, 18].
Classification of total cholesterol con-
centrations into cardiovascular risk cat-
egories was carried out using the Euro-
pean Society of Cardiology’s (ESC) [7] 
current guideline recommendations and 
concentrations ≥190 mg/dL (approx. 
5.0 mmol/L) were defined as elevated. 
In accordance with the recommenda-
tions of the US Adult Treatment Panel III 
(ATP III) in the National Cholesterol Ed-
ucation Program [19] and with Europe-
an Cardiovascular Disease Statistics [10], 
values ≥240 mg/dL (approx. 6.2 mmol/L) 
were additionally defined as highly ele-
vated. For reasons of comparability with 
the current results from the US Nation-
al Health and Nutrition Examination 
Surveys (NHANES), the classification of 
HDL cholesterol concentrations was also 
based on ATP III recommendations and 
values <40 mg/dL (approx. 1.0 mmol/L) 
were defined as low [3, 7]. In contrast 
to total cholesterol, for HDL cholesterol 
the ESC guidelines recommend gender-
specific thresholds (<40 mg/dL for men, 
<45 mg/dL for women) [7].
As part of the standardised comput-
er-assisted personal interview (CAPI) 
by a study physician, information on 
diagnosed dyslipidemia was obtained 
by asking the question: “have you ever 
been diagnosed with dyslipidemia by a 
doctor?” [15, 17]. Dyslipidemia was de-
fined as total cholesterol level ≥190 mg/
dL or the response “yes” to the ques-
tion regarding diagnosed dyslipidemia. 
Here a distinction was made between 
known dyslipidemia (“yes” response to 
the question of diagnosed dyslipidemia, 
regardless of total cholesterol level) and 
previously unknown dyslipidemia (total 
cholesterol level ≥190 mg/dL and a “no” 
or “don’t know” response to the ques-
tion of diagnosed dyslipidemia). The 
percentage of people with known dys-
lipidemia (level of awareness) was cal-
culated as the ratio of the prevalence of 
known dyslipidemia to the overall prev-
alence of dyslipidemia.
As part of the standardised medication 
interview, which features automatic regis-
tration and identification of medications 
being taken, data were collected on the 
current usage of lipid-lowering medica-
tion [15, 17, 20]. All medications included 
in ATC subgroup C10 were defined as lip-
id-lowering. The level of treatment is de-
fined as the proportion of all persons with 
known dyslipidemia who are being treat-
ed for it.
Socioeconomic status was determined 
using an index, which includes details of 
formal education and vocational training, 
occupational status and net household in-
come (weighted by household needs) per-
mitting classification into low, medium 
and high status groups [21].
Statistical analysis
After stratification by age group (18–29, 
30–44, 45–64, 65–79 years) and sex, the 
mean total and HDL cholesterol concen-
trations were calculated with 95% confi-
dence intervals (CI). Age- and gender-
specific prevalence figures (95% CI) for 
elevated (≥190 mg/dL) and highly el-
evated (≥240 mg/dL) total cholester-
ol concentrations and for low (<40 mg/
dL) HDL cholesterol concentrations 
were calculated as percentages of the to-
tal number of people with valid labora-
tory values for the relevant lipid parame-
ters. Age- and gender-specific prevalence 
figures (95% CI) for known dyslipidemia, 
previously undiagnosed dyslipidemia 
and overall dyslipidemia were calculat-
ed as percentages of the total number of 
Tab. 1 Mean (95% confidence interval) total cholesterol (n=7,038) and HDL cholesterol (n=7,045) concentrations among adults in Germany 
according to age group and sex, DEGS1 2008–2011
  Age group (years)
Sex  18–29 30–44 45–64 65–79 Overall
Total cholesterol (mg/dL)
Women 179.2(175.4–183.1) 188.8(185.2–192.4) 217.8(214.6–221.0) 224.7(220.6–228.8) 205.1(202.6–207.5)
Men 170.1(166.3–173.9) 204.1(200.0–208.2) 210.5(206.8–214.3) 204.9(200.9–209.0) 200.1(197.8–202.4)
Overall 174.6(171.8–177.3) 196.6(193.7–199.4) 214.2(211.4–216.9) 215.6(212.7–218.4) 202.6(200.6–204.6)
HDL cholesterol (mg/dL)
Women 60.6(59.3–61.9) 59.7(58.6–60.9) 62.2(61.1–63.4) 60.2(59.0–61.4) 60.9(60.1–61.6)
Men 47.7(46.7–48.7) 47.8(46.6–48.9) 50.1(49.0–51.1) 50.3(49.4–51.2) 49.1(48.4–49.7)
Overall 54.0(53.0–55.1) 53.6(52.7–54.5) 56.1(55.2–57.1) 55.6(54.8–56.5) 55.0(54.4–55.6)
Weighted results for mean values in mg/dL, 38.67 mg/dL =1 mmol/L: cholesterol level in mg/dL × 0.0258598= cholesterol level in mmol/L.
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people with an available total cholester-
ol value and a valid response (“yes”, “no” 
or “don’t know”) to the question regard-
ing diagnosed dyslipidemia. Persons who 
did not respond to the question regard-
ing diagnosed dyslipidemia or for whom 
there were no laboratory readings for to-
tal cholesterol level were excluded from 
these analyses.
Logistic regression was used to analyse 
the correlation between socioeconomic 
status and the following dichotomous tar-
get variables:
a)  high total cholesterol concentrations 
(≥190 mg/dL; ≥240 mg/dL),
b)  level of awareness among all people 
with dyslipidemia, and
c)  level of treatment among people with 
known dyslipidemia.
Age group, sex and place of residence 
(federal states of former West Germany or 
of former East Germany and Berlin) were 
included as covariables.
All the results shown are weighted. 
In order to take into account both the 
weighting and the correlation of partici-
pants within one municipality, confidence 
intervals and p values were determined 
using SPSS 20 procedures for complex 
samples. Differences are considered sta-
tistically significant if the respective 95% 
confidence intervals do not overlap.
Results
Distribution of total cholesterol and 
HDL cholesterol concentrations
The mean total cholesterol concentration 
is 200.1 mg/dL (5.17 mmol/L) among men 
and 205.1 mg/dL (5.30 mmol/L) among 
women (. Tab. 1). Apart from in the age 
group 30–44 years, the age group-specif-
ic means and the overall mean for women 
are significantly higher than for men. The 
mean values for women increase contin-
uously and significantly from the young-
est to the oldest age group. Among men 
the mean total cholesterol concentration 
increases significantly from the youngest 
age group to the 30–44 years age group. 
Among men in the upper age groups there 
is no further significant increase.
The mean HDL cholesterol concentra-
tion is 49.1 mg/dL (1.27 mmol/L) among 
men and 60.9 mg/dL (1.57 mmol/L) 
among women. With respect to the mean 
there are virtually no differences between 
the different age groups among women, 
with the exception of a significantly high-
er mean for the age group 45–64 years as 
compared to age group 30–44 years. Sig-
nificantly higher mean values are evident 
among men 45 years and older compared 
to men in the age groups up to 45 years.
Elevated total cholesterol concentra-
tions ≥190 mg/dL were found in 60.5% 
of women and 56.6% of men (. Tab. 2). 
Highly elevated total cholesterol concen-
trations ≥240 mg/dL are found in 20.3% 
of women and 17.9% of men. Among 
men the prevalence estimates for elevated 
and highly elevated total cholesterol con-
centrations show a sharp increase from 
age group 18–29 years to age group 30–
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Abstract
Interview and laboratory data from the first 
wave of the German Health Interview and Ex-
amination Survey for Adults (DEGS1) from 
2008–2011 were used to provide current es-
timates of the prevalence of dyslipidemia 
which are representative of the population in 
Germany 18–79 years of age. A total of 56.6% 
of men and 60.5% of women 18–79 years 
have elevated serum total cholesterol con-
centrations in excess of the currently rec-
ommended threshold of 190 mg/dL; 17.9% 
of men and 20.3% of women have high-
ly elevated total cholesterol concentrations 
≥240 mg/dL. A total of 19.3% of men and 
3.6% of women have high density lipoprotein 
cholesterol concentrations below 40 mg/dL. 
The overall prevalence of dyslipidemia (to-
tal cholesterol ≥190 mg/dL or medical diag-
nosis of dyslipidemia) is 64.5% for men and 
65.7% for women. Of these, more than half of 
both men and women have previously undi-
agnosed dyslipidemia. Among persons with 
known dyslipidemia, 30.8% take lipid-lower-
ing medication. Dyslipidemia is widely prev-
alent among adults in Germany. More in-
depth analyses will examine time trends in 
the prevalence of dyslipidemia in Germany 
and in an international comparison.
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Verbreitung von Fettstoffwechselstörungen bei 
Erwachsenen in Deutschland. Ergebnisse der Studie zur 
Gesundheit Erwachsener in Deutschland (DEGS1)
Zusammenfassung
Interview- und Labordaten der ersten Er-
hebungswelle der Studie zur Gesundheit 
Erwach sener in Deutschland (DEGS1) 2008–
2011 wurden genutzt, um aktuelle und für 
die Be völkerung im Alter von 18 bis 79 Jahren 
in Deutschland repräsentative Einschätzun-
gen zur Verbreitung von Fettstoffwechsel-
störungen vorzunehmen. Insgesamt haben 
56,6% der Männer und 60,5% der Frauen im 
Alter von 18 bis 79 Jahren ein erhöhtes Se-
rum-Gesamtcholesterin oberhalb des aktu-
ell empfohlenen Grenzwertes von 190 mg/dl; 
17,9% der Männer und 20,3% der Frauen ha-
ben ein stark erhöhtes Gesamtcholesterin von 
≥240 mg/dl. Einen HDL-Cholesterinwert von 
40 mg/dl unterschreiten insgesamt 19,3% der 
Männer und 3,6% der Frauen. Die Gesamt-
prävalenz von Fettstoffwechselstörungen 
(Gesamtcholesterin ≥190 mg/dl oder ärztli-
che Diagnose einer Fettstoffwechselstörung) 
beträgt 64,5% für Männer und 65,7% für 
Frauen; davon haben jeweils mehr als die 
Hälfte der betroffenen Personen eine bislang 
unerkannte Dyslipidämie. Lipid senkende Me-
dikamente werden von 30,8% der Personen 
mit bekannter Dys lipidämie eingenommen. 
Fettstoffwechselstörungen sind bei Erwach-
senen in Deutschland weit verbreitet. Ver-
tiefende Auswertungen werden die zeitliche 
Entwicklung in der Prävalenz von Fettstoff-
wechselstörungen in Deutschland und im in-
ternationalen Vergleich untersuchen.
Schlüsselwörter
Fettstoffwechselstörung · Deutschland ·  
Erwachsene · Gesundheitssurvey · Prävalenz
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44 years. Among men 30 years and older 
there are no further significant differenc-
es between age groups. Among women 
the prevalence of elevated total cholester-
ol concentrations increases continuous-
ly and significantly from approximately a 
third in the youngest age group to 76.1% 
in the age group 45–64 years with respect 
to the 190 mg/dL threshold, and from 6.6 
to 27.2% with respect to the 240 mg/dL 
threshold. There is no further significant 
increase in the oldest age group. The high-
est relative increase in the prevalence of el-
evated cholesterol concentrations among 
women is consistently found between 
age group 30–44 years and age group 45–
64 years.
A total of 19.3% of men and 3.6% of 
women have low HDL cholesterol con-
centrations (. Tab. 2). While no signif-
icant differences according to age group 
are evident among women, the preva-
lence of low HDL cholesterol concentra-
tions decreases significantly in men above 
45 years of age; the prevalence drops from 
over 20% in the younger age groups to 
17.4% in the age group 45–64 years and to 
15.4% in the age group 65–79 years.
Prevalence, level of awareness 
and level of treatment
Taking into account both reported med-
ical diagnoses of dyslipidemia and total 
cholesterol concentrations ≥190 mg/dL, 
for both sexes together almost two thirds 
of all adults aged 18–79 years have dys-
lipidemia (. Tab. 3). The prevalence in-
creases significantly from the youngest 
to the oldest age group, rising from 27.3 
to 81.4% among men and from 34.2 to 
90.0% among women.
Over a third both of men and of wom-
en 18–79 years of age have previously un-
diagnosed dyslipidemia. Dyslipidemia is 
known to be present, on the other hand, 
in a total of 28.1% of men and 27.1% of 
women, with a significant increase in 
prevalence with increasing age and with 
no significant differences between sexes 
(. Tab. 3). The level of awareness of dys-
lipidemia increases in both sexes from 
around 15% in the youngest age group 
to over 60% in the oldest. The respective 
overall levels of awareness are consider-
ably lower than 50% for both sexes, with 
a proportion of 43.6% for men and 41.2% 
for women (data not shown in . Tab. 3). 
Nearly identical results on known dys-
lipidemia were obtained when data were 
included from study participants who 
were surveyed by means of interview on-
ly and were not examined in study cen-
tres (complete data for n=7,947 among 
n=7,988). For example, the prevalence of 
known dyslipidemia was 27.8% (95% CI 
26.2–29.6) among men and 27.5% (95% 
CI 25.9–29.2) among women.
Of people with known dyslipid-
emia 30.8% currently take lipid-lower-
ing medication (level of treatment 29.1% 
among women, and 32.3% among men). 
The level of treatment increases con-
tinuously with increasing age among 
both men and women: 0.0% for persons 
aged 18–29 years, 10.1% for those aged 
30–44 years, 25.8% for those aged 45–
64 years, and 47.3% for those aged 65–
79 years (data not shown in . Tab. 3).
The results from the logistic regres-
sion analyses adjusted for age, sex and 
place of residence show no significant 
correlation between socioeconomic sta-
tus and either presence of elevated to-
tal cholesterol concentrations or level of 
treatment. However, level of awareness of 
having dyslipidemia is significantly high-
er among people with medium socioeco-
nomic status than those with low socio-
economic status (data not shown).
Discussion
According to the available results from 
DEGS1 more than half of men and wom-
en aged 18–79 years in Germany have el-
evated serum total cholesterol concentra-
tions above the currently recommended 
threshold of 190 mg/dL. Of these, ap-
proximately one third of both men and of 
women have highly elevated total choles-
terol concentrations ≥240 mg/dL. 19.3% 
of men, but only 3.6% of women have 
HDL cholesterol concentrations below 
the 40 mg/dL threshold minimum. The 
mean values for total and HDL cholester-
ol concentrations are significantly higher 
for women than for men. Viewed in com-
bination as having a reported medical di-
agnosis of dyslipidemia or elevated total 
cholesterol concentrations, approximate-
ly two thirds of men and women have 
dyslipidemia and in just over 50% of cas-
es of both men and women dyslipidemia 
was previously undiagnosed. The lev-
el of treatment for known dyslipidemia 
overall is 30.8%, with no significant dif-
ference between sexes. There is evidence 
Tab. 2 Prevalence of risk categories for total cholesterol (n=7,038) and HDL cholesterol 
(n=7,045) as percentages (95% confidence interval) according to age group and sex, DEGS1 
2008–2011
  Age group (years)




32.8(28.3–37.6) 42.9(38.0–47.8) 76.1(73.0–79.0) 78.2(74.1–81.9) 60.5(57.9–63.0)
Men 25.9(21.8–30.6) 61.4(56.4–66.1) 65.7(61.4–69.8) 63.5(58.8–68.0) 56.6(54.0–59.1)




6.6(4.5–9.4) 8.9(6.7–11.8) 27.2(24.1–30.4) 33.9(29.8–38.2) 20.3(18.6–22.2)
Men 4.2(2.4–7.0) 19.3(15.9–23.2) 23.2(20.1–26.7) 19.3(15.7–23.6) 17.9(16.1–19.8)




2.4(1.3–4.2) 4.0(2.6–6.1) 3.4(2.3–4.9) 4.8(3.2–7.1) 3.6(2.9–4.5)
Men 21.6(17.5–26.3) 23.2(18.9–28.1) 17.4(14.5–20.8) 15.4(12.5–18.8) 19.3(17.2–21.6)
Overall 12.1(9.9–14.9) 13.8(11.3–16.7) 10.4(8.7–12.4) 9.7(8.1–11.6) 11.4(10.2–12.8)
Weighted results as percentages (95% confidence intervals).
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of socioeconomic inequality with respect 
to level of awareness, but not with respect 
to level of treatment or to the presence of 
elevated total cholesterol concentrations.
Prevalence
Nationally representative data on the 
prevalence of hypercholesterolemia 
among adults in Germany was last pro-
vided by GNHIES98. At that time, 72.6% 
of men and 74.9% of women aged 18–
79 years had total cholesterol concen-
trations of 200 mg/dL or more; 32.2% of 
men and 34.9% of women had concen-
trations of 250 mg/dL or higher [22]. Di-
rect comparison of the values obtained 
in GNHIES98 and DEGS1 is not possi-
ble within the scope of this study, since a 
change in the measurement devices used 
first necessitates cross-calibration of the 
cholesterol level readings from both ex-
amination surveys. However, in view of 
the fact that the thresholds for elevated 
total cholesterol and highly elevated to-
tal cholesterol were lowered in the inter-
im from 200 to 190 mg/dL and from 250 
to 240 mg/dL respectively [7, 10, 19, 23], 
the prevalence of elevated total cholester-
ol observed in DEGS1 suggests that there 
has been a decline.
A previous analysis investigated time 
trends in hypercholesterolemia among 
adults in Germany based on data from 
GNHIES98 and from earlier national 
health surveys carried out as part of the 
German Cardiovascular Prevention Sur-
vey (“Deutsche Herz-Kreislauf-Präven-
tionsstudie”, DHP) [24]. However, the 
data presented here from DEGS1 cannot 
simply be dovetailed with these data due 
to important methodological differences. 
For reasons of comparability among the 
older surveys, for instance, only persons 
aged 30–69 years from former West Ger-
many were included. Furthermore, with 
regard to diagnosed dyslipidemia and 
lipid-lowering medication, all the data 
analysed came from questionnaires that 
participants could fill in themselves, and 
not from medical interviews and a stan-
dardised medication interview, as is the 
case in DEGS1.
Analyses of data from the Nation-
al Health and Nutrition Examination 
Surveys (NHANES) from six cross-sec-
tional surveys between 1999/2000 and 
2009/2010 show a marked drop in the 
prevalence of highly elevated total cho-
lesterol concentrations of 240 mg/dL or 
higher for the population 20 years of age 
and older in the USA. The relative drop 
is slightly greater for men, at approxi-
mately 29% as compared to about 27% 
for women. Prevalence estimates for the 
Caucasian population of the USA result-
ing from the 1999/2000 NHANES survey 
are 11.4% for men and 15.4% for wom-
en [3] and are thus considerably lower 
than comparable estimates for Germany 
based on data from DEGS1. By contrast, 
with figures of 31.9% for men and 11.0% 
for women in the Caucasian population 
of the USA, low HDL cholesterol concen-
trations of less than 40 mg/dL are clearly 
far more common there than in Germa-
ny. Exact comparisons, however, again 
require cross-calibration of survey data, 
since although the laboratory methods 
are comparable in principle, there are dif-
ferences between NHANES and DEGS1 
with respect to preanalytical conditions, 
measurement devices and reagents.
Levels of awareness and treatment
Just over a quarter of men and women 
18–79 years of age have known dyslip-
idemia. This means that there is a lev-
el of awareness in both sexes of con-
siderably less than 50%. To date there 
is no data available from Germany for 
cross-sectional comparison or for as-
sessment of trends. Results from the Be-
havioral Risk Factor Surveillance Sys-
tem (BRFSS) 2009 for the population of 
the USA aged 18 years of age and older 
shows that total cholesterol concentra-
tions had been determined for 77.6% of 
women and 74.5% of men within the pre-
ceding 5 years. The proportion of people 
in this group with known hypercholes-
terolemia was 37.5% for men and 32.6% 
for women [25]. Thus the prevalence of 
known hypercholesterolemia can be es-
timated at just over a quarter, so that the 
results from the BRFSS generally show a 
good level of consistency with the esti-
mates from DEGS1. Periodically collect-
ed representative data are available from 
the BRFSS for the years 2005, 2007 and 
Tab. 3 Prevalence of dyslipidemia when taking into account reported medical diagnosis and total cholesterol concentrations ≥190 mg/dL 
(approx. 5.0 mmol/L) (n=7,013) as percentages (95% confidence intervals) according to age group and sex
  Age group (years)
Dyslipidemia 18–29 30–44 45–64 65–79 Overall
Women
Dyslipidemia overall 34.2(29.8–38.9) 46.6(41.7–51.5) 80.5(77.6–83.2) 90.0(87.0–92.3) 65.7(63.3–68.0)
– Known 5.2(3.4–7.7) 12.7(10.2–15.7) 32.1(29.1–35.2) 54.7(50.8–58.5) 27.1(25.4–28.9)
– Previously undiagnosed 29.1(24.8–33.7) 33.8(29.1–38.9) 48.4(44.6–52.3) 35.3(31.8–39.0) 38.6(36.2–41.0)
Men
Dyslipidemia overall 27.3(23.1–31.9) 64.6(59.8–69.1) 75.6(72.1–78.8) 81.4(77.5–84.7) 64.5(62.0–66.9)
– Known 4.2(2.5–7.1) 18.3(14.9–22.2) 36.6(33.5–39.8) 49.9(45.5–54.4) 28.1(26.2–30.0)
– Previously undiagnosed 23.1(19.1–27.5) 46.3(41.4–51.2) 39.0(35.2–43.0) 31.4(27.4–35.8) 36.4(34.0–38.9)
Overall
Dyslipidemia overall 30.7(27.7–33.8) 55.7(52.2–59.2) 78.1(75.7–80.2) 86.0(83.5–88.2) 65.1(63.1–67.0)
– Known 4.7(3.4–6.4) 15.6(13.4–18.0) 34.3(32.2–36.6) 52.5(49.5–55.4) 27.6(26.4–28.8)
– Previously undiagnosed 26.0(23.1–29.1) 40.2(36.7–43.7) 43.7(40.7–46.8) 33.5(31.0–36.1) 37.5(35.6–39.5)
Weighted results as percentages (95% confidence intervals).
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2009, which confirm a slight, yet con-
tinuous and significant increase both in 
the percentage of persons who under-
went cholesterol measurement and in 
the prevalence of known hypercholes-
terolemia between 2005 and 2009. To-
talling at about 31%, the level of treat-
ment among people with known hyper-
cholesterolemia in DEGS1 was just under 
a third. The levels of treatment observed 
in NHANES 1999–2006 and in the Swiss 
national health interview survey of 2007 
were somewhat higher, at 38% and about 
39% respectively. Compared with previ-
ous data collection waves in the 1990s, 
the level of treatment therefore more 
than doubled both in the USA and in 
Switzerland [26, 27]. Initial analyses on 
trends in the prevalence of dyslipidemia 
and in the levels of awareness and treat-
ment in Germany will become possible 
when data from GNHIES98 and DEGS1 
are compared. The proportion of peo-
ple who have had their cholesterol con-
centration measured within a given time 
frame has not been assessed up to now 
and in future this needs to be considered 
in periodically repeated health surveys.
Methodological strengths 
and limitations
The results presented here on the preva-
lence of dyslipidemia are representative 
of the population in Germany aged 18–
79 years [16]. In conjunction with other 
health-related information, conclusions 
about influencing factors and a range 
of health consequences can be drawn in 
more in-depth analyses.
One important limitation is that it was 
not possible to include measurement re-
sults for LDL cholesterol or triglycerides. 
Concentrations of these are highly de-
pendent upon the time since food was 
last ingested. As examination appoint-
ments were allocated at various times of 
day in DEGS1, fasting level data are avail-
able for only 46% of those examined (no 
random selection).
Information on diagnosed dyslip-
idemia is based on self-reports by par-
ticipants. In addition, the question re-
garding medical diagnosis of dyslipid-
emia did not distinguish between ele-
vated cholesterol concentrations and el-
evated triglyceride concentrations. Iso-
lated triglyceride increases, however, are 
rare, while combinations with hypercho-
lesterolemia occur frequently. The prev-
alence of elevated triglyceride concentra-
tions will be examined in more in-depth 
analyses, in which adjustments will be 
made for the time since last food intake 
as an influencing factor.
Up to now it has not been clarified 
whether the ratio of total to HDL choles-
terol, which is also a cardiovascular risk 
marker, reflects the significance of non-
HDL cholesterol. Non-HDL cholesterol 
is calculated as the difference between to-
tal and HDL cholesterol concentrations. 
Besides LDL cholesterol, it also includes 
the cholesterol fractions attached to very-
low-density lipoprotein (VLDL) [28, 29]. 
Results from recent prospective observa-
tional studies support the prognostic rel-
evance of non-HDL cholesterol to pre-
dicting fatal and non-fatal myocardial in-
farction [30]. More in-depth analyses us-
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